Remibrutinib Dose A

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Hidradenitis Suppurativa

Phase 3

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Active, not recruitingNCT06799000

Novartis PharmaceuticalsHidradenitis Suppurativa

Start: 2025-01-31End: 2027-10-04Updated: 2026-08-20

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

Active, not recruitingNCT06840392

Novartis PharmaceuticalsHidradenitis Suppurativa

Start: 2025-03-20End: 2027-10-21Updated: 2026-08-21